Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
Myriad Genetics (NASDAQ: MYGN) has appointed Jennifer Fox as Chief Legal Officer, effective September 3, 2024. Fox brings nearly two decades of legal experience in the life sciences sector, with expertise in intellectual property, litigation, and regulatory matters. Her responsibilities will include support and counsel for legal affairs, IP, patent protection, M&A, litigation, regulatory and quality assurance, compliance, privacy, and government affairs.
Fox previously served as Executive VP of External Affairs at Emergent BioSolutions, overseeing legal functions, government and public affairs, communications, and ESG initiatives. She holds a J.D. from North Carolina Central University, an M.S. in Biochemistry and Molecular Biology, and a B.S. in Biology from the University of Toledo.
Myriad Genetics (NASDAQ: MYGN) ha nominato Jennifer Fox come Chief Legal Officer, a partire dal 3 settembre 2024. Fox porta con sé quasi due decenni di esperienza legale nel settore delle scienze della vita, con competenze in proprietà intellettuale, contenzioso e questioni regolatorie. Le sue responsabilità includeranno supporto e consulenza per questioni legali, proprietà intellettuale, protezione dei brevetti, fusioni e acquisizioni, contenzioso, regolamentazione e assicurazione della qualità, conformità, privacy e affari governativi.
In precedenza, Fox ha ricoperto il ruolo di VP esecutivo degli Affari Esterni presso Emergent BioSolutions, supervisionando le funzioni legali, gli affari governativi e pubblici, le comunicazioni e le iniziative ESG. Ha conseguito un J.D. presso la North Carolina Central University, un M.S. in Biochimica e Biologia Molecolare e un B.S. in Biologia presso l'Università di Toledo.
Myriad Genetics (NASDAQ: MYGN) ha nombrado a Jennifer Fox como Directora Legal, con efecto a partir del 3 de septiembre de 2024. Fox aporta casi dos décadas de experiencia legal en el sector de las ciencias de la vida, con especialización en propiedad intelectual, litigios y asuntos reglamentarios. Sus responsabilidades incluirán apoyo y asesoría en asuntos legales, propiedad intelectual, protección de patentes, fusiones y adquisiciones, litigios, regulación y aseguramiento de la calidad, cumplimiento, privacidad y relaciones gubernamentales.
Anteriormente, Fox se desempeñó como Vicepresidenta Ejecutiva de Asuntos Externos en Emergent BioSolutions, supervisando funciones legales, cuestiones gubernamentales y públicas, comunicaciones e iniciativas ESG. Tiene un J.D. de la North Carolina Central University, un M.S. en Bioquímica y Biología Molecular y un B.S. en Biología de la Universidad de Toledo.
Myriad Genetics (NASDAQ: MYGN)가 Jennifer Fox를 최고 법률 책임자(Chief Legal Officer)로 임명하였습니다. 임기는 2024년 9월 3일부터 시작됩니다. Fox는 생명 과학 분야에서 거의 20년의 법률 경험을 갖추고 있으며, 지적 재산권, 소송, 규제 문제에 대한 전문성을 지니고 있습니다. 그녀의 책임에는 법률 사안, 지적 재산권, 특허 보호, 인수합병, 소송, 규제 및 품질 보증, 준수, 개인 정보 보호, 정부 업무에 대한 지원 및 자문이 포함됩니다.
Fox는 Emergent BioSolutions에서 외부 관계의 최고 부사장으로 근무하면서 법률 기능, 정부 및 공공 업무, 커뮤니케이션, ESG 이니셔티브를 총괄했습니다. 그녀는 노스캐롤라이나 중앙 대학교(North Carolina Central University)에서 J.D.를 취득하였고, 토레도 대학교(University of Toledo)에서 생화학 및 분자 생물학 석사(M.S.)와 생물학 학사(B.S.)를 취득하였습니다.
Myriad Genetics (NASDAQ: MYGN) a nommé Jennifer Fox au poste de Chief Legal Officer, à compter du 3 septembre 2024. Fox possède près de deux décennies d'expérience juridique dans le secteur des sciences de la vie, avec une expertise en propriété intellectuelle, litiges et questions réglementaires. Ses responsabilités incluront le soutien et les conseils pour les affaires juridiques, la propriété intellectuelle, la protection des brevets, les fusions et acquisitions, les litiges, la réglementation et l'assurance qualité, la conformité, la protection de la vie privée et les affaires gouvernementales.
Avant cela, Fox a été vice-présidente exécutive des affaires externes chez Emergent BioSolutions, supervisant les fonctions juridiques, les affaires gouvernementales et publiques, les communications et les initiatives ESG. Elle est titulaire d'un J.D. de la North Carolina Central University, d'un M.S. en biochimie et biologie moléculaire, et d'un B.S. en biologie de l'Université de Toledo.
Myriad Genetics (NASDAQ: MYGN) hat Jennifer Fox zum Chief Legal Officer ernannt, mit Wirkung zum 3. September 2024. Fox bringt fast zwei Jahrzehnte juristische Erfahrung im Bereich der Lebenswissenschaften mit, mit Fachkenntnissen in geistigem Eigentum, Prozessführung und regulatorischen Angelegenheiten. Zu ihren Aufgaben gehören die Unterstützung und Beratung in rechtlichen Angelegenheiten, geistigem Eigentum, Patentschutz, Fusionen und Übernahmen, Prozessführung, Regulierung und Qualitätssicherung, Compliance, Datenschutz und Regierungsangelegenheiten.
Zuvor war Fox Executive VP für externe Angelegenheiten bei Emergent BioSolutions und überwachte die juristischen Funktionen, Regierungs- und Öffentlichkeitsarbeit, Kommunikation sowie ESG-Initiativen. Sie hat einen J.D. von der North Carolina Central University, einen M.S. in Biochemie und Molekularbiologie sowie einen B.S. in Biologie von der University of Toledo.
- Appointment of an experienced legal professional with nearly two decades in the life sciences sector
- Expertise in important areas such as intellectual property, litigation, and regulatory matters
- Previous executive experience in overseeing legal functions and external affairs at a biotech company
- None.
SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as Chief Legal Officer, effective September 3, 2024.
Fox brings nearly two decades of legal experience in the life sciences sector. Her expertise spans intellectual property, litigation, and regulatory matters, gained through roles in both in-house and private practice settings at industry-leading companies. As Chief Legal Officer, Fox’s responsibilities will encompass a wide range of areas, including support and counsel for all legal affairs, intellectual property, patent protection, mergers and acquisitions, litigation, regulatory and quality assurance, compliance, privacy, and government affairs.
“Jennifer is a seasoned legal leader with a deep understanding of the biotech industry landscape and a remarkable ability to build cohesive teams,” said Paul J. Diaz, President and CEO of Myriad Genetics. “Her industry experience and expertise, combined with her integrity, practical insight, and operational excellence, will be essential in guiding our legal strategy. We are immensely fortunate to welcome such a skilled legal expert to our executive team at Myriad Genetics.”
Fox most recently served as the Executive Vice President of External Affairs for Emergent BioSolutions where she was responsible for overseeing legal functions, government and public affairs, communications, and ESG initiatives. Prior to that role, she held positions with Brinks, Gilson & Lione, Novozymes North America and GSK. Fox holds a J.D. from North Carolina Central University, an M.S. in Biochemistry and Molecular Biology from the University of Toledo, and a B.S. in Biology, also from the University of Toledo.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that Fox will be essential in guiding the company’s legal strategy. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Media Contact:
Glenn Farrell
(385) 318-3718
PR@myriad.com
Investor Contact:
Matt Scalo
(801) 584-3532
IR@myriad.com
To view Jennifer Fox: Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer, please visit the following link: https://www.globenewswire.com/NewsRoom/AttachmentNg/89f4e64c-0023-4324-aada-018f70199e3f
FAQ
When will Jennifer Fox start as Chief Legal Officer at Myriad Genetics (MYGN)?
What are Jennifer Fox's main responsibilities as Chief Legal Officer at Myriad Genetics (MYGN)?
What was Jennifer Fox's previous position before joining Myriad Genetics (MYGN)?
What educational background does Jennifer Fox bring to her role at Myriad Genetics (MYGN)?
